Related Experiment Video
Updated: Feb 7, 2026

In Vivo Imaging to Measure Spontaneous Lung Metastasis of Orthotopically-injected Breast Tumor Cells
Published on: June 23, 2022
Oncolytic Adenovirus rAd.DCN Inhibits Breast Tumor Growth and Lung Metastasis in an Immune-Competent Orthotopic
Huiqiang Zhao1,2, Hao Wang2, Fanxuan Kong2
11 Department of Cadre Health Care, Navy General Hospital, Beijing, P.R. China.
Abstract:
The majority of advanced breast cancer patients develop distal metastasis, including lung and bone metastasis. However, effective therapeutic strategies to prevent metastasis are still lacking. Decorin is a natural inhibitor of transforming growth factor β, which plays a pivotal role in tumor metastasis. An oncolytic adenovirus expressing decorin, rAd.DCN, has been developed previously. In an immune-competent breast tumor (4T1) model, intratumoral (i.t.) as well as intravenous (i.v.) delivery of rAd.DCN inhibited growth of orthotopic tumors and spontaneous lung metastasis. It was shown that i.t. delivery of rAd.DCN produced higher levels of transgene expression and evoked stronger oncolysis of the tumors compared to i.v. delivery. However, i.v. delivery resulted in higher amount of virus accumulation in the lungs and produced stronger responses to prevent tumor lung metastasis. Oncolytic adenovirus-mediated decorin expression in the tumors downregulated the decorin target genes and decreased epithelial mesenchymal transition markers. Decorin expression in lung tissues also increased Th1 cytokine expression, such as interleukin (IL)-2, IL-12, and tumor necrosis factor α, and decreased Th2 cytokines, such as transforming growth factor β and IL-6. Moreover, rAd.DCN treatment induced strong systemic inflammatory responses and upregulated CD8+ T lymphocytes. In conclusion, rAd.DCN inhibits tumor growth and lung metastasis of breast cancer via regulating wnt/β-catenin, vascular endothelial growth factor (VEGF), and Met pathways, and modulating the antitumor inflammatory and immune responses. Considering that i.v. delivery was much more effective in preventing lung metastasis, systemic delivery of rAd.DCN might be a promising strategy to treat breast cancer lung metastasis.
Insights
Intravenous delivery of decorin-expressing oncolytic adenovirus (rAd.DCN) effectively inhibits breast cancer lung metastasis by modulating immune responses and key signaling pathways.
Area of Science:
- Oncology
- Gene Therapy
- Immunology
Background:
- Advanced breast cancer frequently metastasizes to distant sites like the lungs and bones.
- Current therapeutic strategies to prevent metastasis remain limited.
- Decorin, a natural inhibitor of transforming growth factor-beta (TGF-β), plays a role in suppressing tumor metastasis.
Purpose of the Study:
- To evaluate the efficacy of an oncolytic adenovirus expressing decorin (rAd.DCN) in preventing breast cancer metastasis.
- To compare the effects of intratumoral (i.t.) versus intravenous (i.v.) delivery of rAd.DCN.
- To elucidate the underlying molecular and immunological mechanisms of rAd.DCN's anti-metastatic effects.
Main Methods:
- Utilized an immune-competent 4T1 breast tumor model in mice.
- Administered rAd.DCN via both intratumoral and intravenous routes.
- Assessed tumor growth, spontaneous lung metastasis, transgene expression, and immune cell responses (cytokines, CD8+ T lymphocytes).
- Analyzed the regulation of key signaling pathways including wnt/β-catenin, VEGF, and Met.
Main Results:
- Both i.t. and i.v. delivery of rAd.DCN inhibited primary tumor growth and lung metastasis.
- Intravenous delivery led to higher virus accumulation in lungs and stronger inhibition of lung metastasis compared to i.t. delivery.
- rAd.DCN downregulated decorin target genes and epithelial-mesenchymal transition markers.
- Decorin expression modulated Th1/Th2 cytokine balance, enhanced systemic inflammation, and increased CD8+ T lymphocytes.
Conclusions:
- rAd.DCN effectively inhibits breast cancer growth and lung metastasis through multiple mechanisms.
- Intravenous delivery of rAd.DCN is a promising strategy for treating breast cancer lung metastasis.
- The therapeutic effect involves regulating key oncogenic pathways and modulating antitumor immune responses.
More Related Videos
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
09:53Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies
Published on: November 30, 2016
Related Concept Videos
What is the Immune System?
Feedback Inhibition
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Lung Capacity
Growth Models with Integration: Problem Solving
Exponential Equations for Modeling Growth